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Abstract: We determined previously that nitric oxide (NO) modulates the nerve growth factor (NGF)-mediated increases 
in amyloid precursor protein (APP) levels in PC12 cells. To elucidate potential mechanisms, the effects of NGF and NO 
synthase (NOS) inhibitors on APP mRNA levels and protein stability were evaluated. Surprisingly, treatment of PC12 
cells with NGF resulted in decreased levels of APP695 and APP751/770 mRNA. Therefore, the effect of NGF on APP 
protein stability was examined using the translation inhibitor, cycloheximide. Under these conditions, NGF did not alter 
the rate of APP degradation, suggesting that NGF may be enhancing the translation rate of APP. Since NOS inhibitors at-
tenuate the NGF-mediated increase in APP levels, their effect on APP mRNA levels and protein stability was also as-
sessed. S-methylisothiourea (S-MIU), selective for inducible NOS, decreased both APP695 and APP751/770 mRNA lev-
els while the non-selective NOS inhibitor, N
-nitro-L-arginine methylester (L-NAME) had no effect. In both control and 
NGF-treated PC12 cells, S-MIU increased the half-life of APP, with the greatest effect observed with the APP695 iso-
form. Based on these data we propose that in PC12 cells, NGF increases APP levels through enhanced translation rate and 
that NO, which modulates the NGF-induced increase in APP protein, also regulates APP mRNA levels and could play a 
role in APP processing. 
Keywords: Amyloid precursor protein, mRNA, nerve growth factor, nitric oxide, PC12 cells, protein stability. 
INTRODUCTION 
  Currently, elevated levels of amyloid -protein (A) are 
most often implicated in the progression of Alzheimer’s dis-
ease (AD; reviewed in [1]). A is produced during the nor-
mal cleavage of the glycoprotein amyloid precursor protein 
(APP), which is expressed in the membrane of neurons and 
glial cells [2]. Alternative splicing of the APP gene results in 
the generation of several isoforms, ranging in size from 365 
to 770 amino acids, with APP695 being the most abundantly 
expressed isoform in the brain [3-5]. While many studies 
have focused on APP metabolism and the production of A, 
the mechanisms involved in regulating APP isoform expres-
sion have not been elucidated.  
  Nerve growth factor (NGF), a neurotrophin reported to 
benefit AD patients [6], has also been found to modulate the 
levels and post-translational processing of APP. Several 
studies, using PC12 cells or primary neurons have reported 
that NGF increases APP mRNA and protein levels [7 - 10]. 
In PC12 cells, this is primarily the result of an up-regulation 
of the APP695 isoform [7, 10]. The levels of all three iso-
forms of nitric oxide synthase (NOS) are also increased fol-
lowing treatment with NGF [11, 12] and we found that NOS 
inhibitors attenuate the increase in APP protein levels caused 
by NGF [7]. Interestingly, we also found that this inhibition 
of NOS only partially attenuated the increase in APP pro-
moter activation mediated by NGF [7] suggesting that NGF- 
signal transduction pathways and NO may be influencing 
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the rate of APP mRNA or protein synthesis or degradation in 
addition to altering gene transcription. Therefore, in the pre-
sent study we investigated the effects of NGF and NOS in-
hibitors, alone and in combination, on APP mRNA levels 
and protein stability in PC12 cells. We determined previ-
ously that the non-selective inhibitor, N
-nitro-L-arginine 
methylester (L-NAME) and s-methylisothiourea (S-MIU), 
selective for the inducible NOS isoform [13], inhibited NOS 
activity in PC12 cells [11] and modulated NGF-induced APP 
expression [7]. Therefore these inhibitors were used to exam-
ine the role of NO on steady-state APP mRNA and protein 
levels. APP protein stability was assessed in PC12 cells ex-
posed to NGF and/or NOS inhibitors followed by treatment 
with the translation inhibitor cycloheximide.  
MATERIALS AND METHODS 
Materials 
  Dulbecco's modified Eagle medium (DMEM), horse se-
rum, gentamycin, Trizol and reverse transcription reagents 
were supplied by Invitrogen (Carlsbad, CA) and fetal bovine 
serum was purchased from HyClone Laboratories (Logan, 
UT). Harlan Bioproducts for Science (Indianapolis IN) was 
the supplier for NGF and Sigma Aldrich (St. Louis, MO) the 
source for L-NAME, S-MIU, actinomycin D, cycloheximide 
and the mouse monoclonal -tubulin antibody. The complete 
mini tablets were obtained from Roche Diagnostics (Laval, 
QC), the protein standards and sodium dodecyl sulfate (SDS) 
sample buffer were purchased from New England Biolabs 
(Ipswich, MA) and the SYBR green polymerase chain reac-
tion reagents were from Qiagen (Mississauga, ON). Mouse 
monoclonal anti-APP was purchased from Chemicon Inter-32    The Open Biochemistry Journal, 2012, Volume 6  MacKinnon et al. 
national (Temecula, CA) and Amersham/GE Health Care 
(Piscataway, N.J.) supplied the Hybond blotting membrane, 
sheep anti-mouse IgG, Rediprime
® random primer labelling 
system and the enhanced chemiluminescence (ECL) kit. All 
other chemicals were purchased either from Fisher Scientific 
(Ottawa, ON) or DiaMed Laboratories (Mississauga, ON) 
and were electrophoresis or molecular grade.  
PC12 Cell Culture  
  PC12 cells were maintained, plated and treated as de-
scribed previously [7, 11]. Media consisted of DMEM sup-
plemented with 5% fetal bovine serum, 5% horse serum and 
50 g/mL gentamycin and cells were plated onto Corning 
CellBind coated dishes at a density of 2.0 million cells per 
100 mm dish for RNA analysis and at a density of 1.0 mil-
lion cells per 60 mm dish for protein analysis, 24 h prior to 
experiments.  
NGF and Inhibitor Treatments 
  To determine a temporal profile for the effects of NGF 
on APP levels, samples from untreated PC12 cells or cells 
treated with 50 ng/mL NGF were collected at 12 or 24 hour 
intervals for a maximum of 96 h. The cell culture media and 
NGF treatment was replaced every 48 hours. The role of NO 
on APP mRNA levels or protein stability was examined in 
PC12 cells treated with 20 mM L-NAME or 0.5 to 2.0 mM 
S-MIU alone or 1 h before treatment with NGF [7, 11]. The 
effect of NGF on APP mRNA half-life was assessed in PC12 
cells treated for 24 h with NGF followed by treatment with 1 
g/mL actinomycin D for 1, 2, 4 or 8 h. The effect of NGF 
on APP protein translation was assessed in PC12 cells 
treated for 72 h with NGF or NOS inhibitors, alone or in 
combination, followed by treatment with 10 g/mL cyclo-
heximide for 0.25, 0.5, 1 or 2 h. For protein studies, media 
and treatments were replaced at the 48 h time-point, as de-
scribed above.  
Immunoblot Analysis 
  PC12 cell samples were obtained and analyzed as de-
scribed previously [7]. Briefly, cells were lysed in 250 L of 
radioimmunoprecipitation assay (RIPA) buffer, rocked on 
ice for 15 min, sonicated and centrifuged for 15 min at 17 
530 g. Supernatant protein content was determined by the 
method of Bradford [14] and 35 g of cell lysate was boiled 
in SDS sample buffer. Proteins were separated by 10% 
SDS/polyacrylamide gel electrophoresis and transferred onto 
Hybond-C nitrocellulose membranes using a Trans-blot 
semidry transfer unit (Bio-Rad Laboratories, Mississauga, 
ON). Membranes were blocked for 1 h in 5% non-fat milk in 
TRIS-buffered saline (TBS) containing 0.1% Tween-20 
(TBS-T). Membranes were incubated over night in 1:50,000 
anti--tubulin or 1:500 anti-APP in 5% non-fat milk in TBS-
T. Proteins were detected following a 1 h exposure to1:2000 
horseradish peroxidase conjugated sheep anti-mouse IgG in 
5% non-fat milk in TBS-T, ECL and subsequent scanning of 
the membranes with the STORM 860 (Molecular Dynamics, 
subsidiary of Amersham). Relative protein levels were and 
quantified densitometrically using Imagequant software 
(Molecular Dynamics). 
Quantitative RT- PCR 
  Total RNA was isolated from PC12 cells using Trizol. 
Extracted RNA (5 g) was reverse transcribed with Super-
script II, using oligo-dt as the primer, for 75 min at 43
oC and 
the cDNA generated was used for real-time PCR. All PCR 
reactions were performed in a LightCycler (Roche Diagnos-
tics) using SYBRgreen PCR reagents in a final volume of 10 
L. Each cycle began with an initial activation phase at 95
oC 
for 15 min followed by 45 cycles of 15 s at 95
oC, 20 s at 
55
oC and 15 s at 72
oC. The primers used to amplify APP and 
the house keeping gene beta-2 microglobulin were: APP 
forward: 5’ cgt ttg tga gcc cca tct tc 3’, APP reverse: 5’ ttc 
ctc ctc ttc ggc tac ttc 3’, beta-2 microglobulin forward: 5’ tga 
ccg tga tct ttc tgg gtg 3’ and beta-2 microglobulin reverse: 5’ 
atc tga ggt ggg tgg aac ctg 3’. 
Northern Blot Analysis 
  Total RNA was isolated from PC12 cells as described 
above. For each sample, 20  µg of RNA was subjected to 
electrophoresis
 in 0.8% formaldehyde/agarose gels and trans-
ferred to nylon membranes
  (Hybond N) using a semi-dry 
transfer apparatus (Bio-Rad Laboratories). Membranes were 
UV-cross-linked and prehybridized at 42  °C
  for 1  h in 
6  ×  SSPE (saline/sodium phosphate/EDTA), 0.5% SDS,
 
5 × Denhardts' reagent, 20 µg/mL salmon sperm DNA, and 
50% formamide.
 Probes were generated for rat APP695 and 
APP751/770 by PCR using the following primers: APP695 
forward: 5’ tga aaa gct tgt agt ccg agt tcc cac gac 3’ , 
APP695 reverse: 5’ tgt tac tag tct tcc tgt tcc aga gat tcc aac 
3’, APP751/770 forward: 5’ act gaa gct ttc ttt tac ggc gga tgt 
g 3’ and APP751/770 reverse: 5’ aag aac tag tac ctc tct ttg 
gct ttc tgg 3’ A cDNA probe for murine 7S RNA [15] was 
used to normalize RNA loading. The probes were radio-
labelled using 50 µCi of [ -
32P]dCTP and the Rediprime
® 
random primer labelling system and incubated with the 
membranes at
 42 °C for 18 h in a solution identical to the 
prehybridization
  solution. Membranes were washed twice
 
(15  min each) in 2  ×  SSC, 1% SDS at 42  °C and once 
(30 min) in 0.1× SSC, 0.1% SDS at 55 to 60 °C. For APP695 
or APP751/770, the blots were left in phosphoimaging cas-
settes for 48 h, while the 7s blots were exposed for 30 min. 
The phosphoimaging screens were then scanned on the 
STORM 860 (Molecular Dynamics) for visualization and the 
bands analyzed densitometrically using Imagequant software 
(Molecular Dynamics). 
Data Analysis and Statistics  
  Real-time PCR analysis was carried out using RelQuant 
software (Roche Diagnostics) and APP levels were quanti-
fied relative to beta-2 microglobulin levels in the same sam-
ple. For the analysis of both western and northern blots, 
bands for APP, -tubulin (for protein) or 7s (for RNA) were 
analyzed densitometrically and levels expressed as a per-
centage of the total amount of each protein or mRNA level 
present on the entire blot [as in 7]. APP protein levels were 
then expressed relative to -tubulin and APP RNA normal-
ized to 7s levels within the same sample. At least 4 inde-
pendent experiments were run for each data point and the 
data are presented as the mean  standard error of the mean 
(SEM). All data were assessed for normality and homogene-Nitric Oxide Modulates Amyloid Precursor Protein Expression  The Open Biochemistry Journal, 2012, Volume 6    33 
ity of variance and statistical analysis was carried out using a 
one-way analysis of variance (ANOVA). To determine sig-
nificant differences between treatment groups, ANOVA was 
followed by either the Dunnett or Tukey-Kramer multiple 
comparisons test. Mean values were considered different if 
p<0.05. 
RESULTS 
Effect NGF on APP mRNA Levels 
  To assess the temporal effects of NGF on APP mRNA, 
PC12 cells were treated with 50 ng/mL NGF and the samples 
collected at 24 h intervals for a maximum of 96 h.  Using 
primers that detected total APP mRNA (both APP695 and 
751/770 isoforms), real-time PCR analysis revealed a 
decrease in the steady-state levels of APP mRNA (Fig. 1A).  
To confirm these findings and to determine whether this 
NGF-mediated decrease was isoform selective, PC12 cells 
were treated with 50 ng/mL of NGF, RNA harvested at 12 h 
intervals for 96 h and mRNA levels evaluated using probes 
generated to detect APP695 and APP751/770 specifically by 
northern blot analysis (Fig. 1B). Again, densitometric 
analysis revealed that steady-state mRNA levels of APP 
were reduced following NGF treatment, with significant 
decreases in APP695 mRNA detected from 36 to 96 h   
(Fig.1C; * p < 0.05) and a significant decrease in 
APP751/770 detected between 24 and 96 h (Fig. 1D; *p < 
0.05; *** p < 0.001) of NGF treatment.  The effect of NGF 
on APP mRNA half-life was examined in samples obtained 
from cells cultured with or without NGF for 24 h and treated 
 
 
 
Fig. (1). Analysis of steady-state APP mRNA expression. (A) Real-time PCR analysis of total APP mRNA relative to beta-2 microglobulin 
levels following treatment with 50 ng/mL NGF. (B) Representative northern blots of APP695 (upper panel), APP751/770 (middle panel) and 
7s (lower panel) expression in control (untreated) and NGF (50 ng/mL) treated PC12 cells. (C) Densitometric analysis of steady-state 
APP695 mRNA expression normalized to 7s. Treatment with NGF from 36 to 96 h resulted in a statistically significant (*p < 0.05) decrease 
in APP695 mRNA expression. (D) Densitometric analysis of steady-state APP751/770 mRNA expression normalized to 7s. Treatment with 
NGF from 24 to 96 h resulted in a statistically significant (*p<0.05; ***p<0.001) decrease in APP751/770 mRNA expression. (E) Real-time 
PCR analysis of total APP mRNA relative to beta-2 microglobulin levels in control and 24 h NGF exposed cells treated with actinomycin D 
for 1, 2, 4 or 8 h. Significantly lower levels of relative APP mRNA were observed following treatment with NGF in the absence of actino-
mycin D and when treated with actinomycin D for 1 or 2 h (*p<0.05). Data are presented as the mean ± SEM and represent 4 (E), 5 (A) or 6 
(B, C and D) independent experiments. Statistical significance was determined by performing a one-way ANOVA followed by the Dunnett 
test to determine any significant differences between control and each time point.  
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with actinomycin D for 1, 2, 4 and 8 h. Since the effect of 
NGF was not isoform specific, APP mRNA levels were 
assessed using real-time PCR with primers that detected total 
APP (Fig. 1E). The level of APP mRNA was lower in cells 
treated with NGF relative to control in the absence of 
actinomycin D and following treatment with actinomycin D 
for 1 and 2 h (*p< 0.05). Although the estimated APP 
mRNA half-life was shorter in NGF treated cells (2.1 h) 
compared to control (2.8 h) this difference was not 
statistically significant.  
Effect of Cycloheximide D on APP Protein Levels  
  To examine whether NGF influences APP protein 
stability, cells were cultured in the presence or absence of 
NGF for 72 h and treated with cycloheximide from 15 min to 
2 h. Representative western blots depicting APP and -
tubulin levels under these treatment conditions are presented 
in Fig. (2A). We determined previously that the highest 
protein band in the upper panel of Fig. (2A) shows mature 
APP751/770 and the immature APP695 isoform is depicted 
in the lowest band [7]. The middle band in this upper panel, 
which can sometimes be seen as 2 distinct bands, contains 
both immature APP751/770, and mature APP695. Relative 
expression of -tubulin levels from the same samples is 
shown in the bottom panel of Fig. (2A). Following 
densitometric analysis, protein levels of the highest 
molecular weight APP isoform (Fig. 2B) and the lower band 
(Fig. 2D) that contained the immature APP695 isoform were 
significantly higher than control (*P<0.05) prior to the 
addition of cycloheximide but no difference in the levels or 
rate of decay of APP was observed at any of the time points 
following treatment with cycloheximide. The levels of 
immature APP751/770 and mature APP695 (Fig. 2C) was 
not different following 72 h of NGF treatment in the 
presence or absence of cycloheximide at any of the time 
points examined. 
 
Fig. (2). APP protein levels in control and NGF-treated PC12 cells in the presence or absence of cycloheximide. (A) Representative im-
munoblots obtained from lysates of control (untreated) and NGF (50 ng/mL) treated PC12 cells treated with 10 g/mL cycoheximide from 
30 min to 2 h. Samples were separated by SDS-PAGE and transferred to nitrocellulose membranes. The top panel represents total APP ex-
pression and the bottom panel shows the corresponding -tubulin levels in each sample. The top APP band represents mature (m) 
APP751/770, the middle APP band corresponds to immature (i) APP751/770 and mAPP695 and the lowest molecular weight APP band cor-
responds to iAPP695. Densitometric analysis of mature APP751/770 (B) immature APP751/770 and mature APP695 (C) and immature 
APP695 (D) protein levels normalized to -tubulin. Treatment with NGF for 72 h resulted in a statistically significant (* p < 0.05) increase 
in mature APP751/770 and immature APP695 levels. Data are presented as the mean ± SEM and represent 6 independent experiments. Sta-
tistical significance was determined by performing a one-way ANOVA followed by Tukey-Kramer’s multiple comparisons test to determine 
any significant differences between control and NGF treated samples at each time point. 
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Effect of L-NAME or S-MIU on APP mRNA Levels and 
Protein Stability 
  Northern blot analysis was used to evaluate the effects of 
NOS inhibitors on APP mRNA levels.  Densitometric 
analysis of mRNA levels for APP695 and APP751/770 
normalized to 7s following treatment with NGF and NOS 
inhibitors are depicted in Fig. (3).  For both APP695 (Fig. 
3A) and APP751/770 (Fig. 3B) there was a significant 
decrease in steady-state mRNA levels following treatment 
with 1.5 and 2.0 mM S-MIU in comparison to control levels 
(*** p < 0.001). NGF also decreased the level of both 
transcripts but the levels of APP695 and APP751/770 
mRNA were not different in samples obtained from NGF 
treated cells cultured with or without S-MIU.  In contrast, 
treatment with L-NAME did not alter APP mRNA levels in 
either the presence or absence of NGF.   
  To determine whether NOS inhibition affected APP 
protein stability, control (untreated) and NGF-treated cells 
were grown in the presence or absence of 2.0 mM S-MIU 
and treated with cycloheximide from 15 min to 2 h. 
Densitometric analysis of APP isoform protein levels are 
presented in Fig. (4). There was no difference in the level of 
the highest molecular weight APP isoform in samples 
obtained from control or S-MIU-treated cells but a 
statistically significant difference between the levels of this 
isoform in control and S-MIU treated cells following 
treatment with cycloheximide for 60 and 120 min was 
observed (*p<0.05; Fig. 4A). The levels of immature 
APP751/770 isoform and mature APP695, which were 
quantified together (Fig. 4B) and immature APP695 isoform 
(Fig. 4C) were significantly lower in cells treated with S-
MIU as compared to control (**p<0.01).  In the presence of 
cycloheximide, the level of these APP isoforms declined 
steadily, while in the presence of S-MIU and cycloheximide, 
the levels of APP protein remained constant resulting in 
significantly lower levels of the smaller isoforms of APP in 
control cells as compared to those treated with S-MIU 
following treatment with cycloheximide for 60 and 120 min 
(*p<0.05; **p<0.01). In the presence of NGF, there was no 
difference in the levels or the rate of decay of mature 
APP751/770 in cells cultured with or without S-MIU (Fig. 
4D). In cells treated with NGF and S-MIU, the relative level 
of the middle APP band, containing immature APP751/770 
and mature APP695 (Fig. 4E) was significantly lower in 
NGF-treated cells pretreated with S-MIU prior to 
cycloheximide treatment (*p<0.05) and significantly higher 
following 2 h of exposure to cycloheximide (*p<0.05) when 
compared to cells treated with NGF alone. Densitometric 
analysis of the band containing the immature APP695 
isoform (Fig. 4F) revealed a significantly lower level of this 
APP isoform in cells treated with NGF and S-MIU as 
compared to those treated with NGF alone (**p<0.01).  In 
the presence of cycloheximide, immature APP695 levels in 
cell extracts of NGF-treated cells declined steadily over time, 
while in cells receiving both NGF and S-MIU, the level of 
this APP isoform remained constant resulting in significantly 
higher levels of immature APP695 in cells that received 
NGF and S-MIU compared to those exposed to NGF alone at 
the 120 min cycloheximide treatment time point (**p<0.01). 
 
Fig. (3). Northern blot analysis of steady-state APP and 7s mRNA 
levels after treatment with increasing concentrations of S-MIU and 
20mM L-NAME in the presence or absence of NGF. (A) APP695 
mRNA levels: NGF (50 ng/mL) alone and 1.5 or 2.0 mM S-MIU 
with and without NGF significantly (* p < 0.05; ** p < 0.01; *** p 
< 0.001) decreased APP695 mRNA levels as compared to control. 
(B) APP751/770 mRNA levels: NGF alone, and the two concentra-
tions of S-MIU in the presence or absence of NGF significantly (** 
p < 0.01; *** p < 0.001) decrease in APP751/770 mRNA levels as 
compared to control. Data are presented as the mean ± SEM and 
represent 6 independent experiments. Statistical significance was 
determined by a one-way ANOVA followed by the Dunnett test. 
DISCUSSION 
  In PC12 cells, NGF treatment induces neurite outgrowth 
and increases the levels of APP protein [7, 10, 16 - 18], and 
we reported previously that NO modulates both of these ac-
tions of NGF [7]. To assess the mechanisms through which 
NO regulates these actions, we examined the effects of NGF, 
L-NAME and S-MIU on APP mRNA levels and protein sta-
bility. While NGF did increase APP protein levels, steady-
state APP mRNA levels were decreased in NGF-treated 
PC12 cells. Although the estimated half-life of APP mRNA 
was lower in NGF-treated cells compared to control, this 
difference was not statistically significant. It was also dem-
onstrated that the administration of NGF did not alter the 
stability of APP protein. These data suggest that, NGF may 
elevate APP levels in part through enhanced translation. A 
similar decrease in APP mRNA levels was observed in PC12 
cells grown in the presence of the iNOS selective inhibitor, 
S-MIU. In contrast, L-NAME, the non-selective inhibitor, 
did not alter APP mRNA levels and neither inhibitor affected 
the ability of NGF to lower APP mRNA expression. In addi-
tion, treatment of PC12 cells with S-MIU resulted in a de-
crease in the level of APP protein, but an increase in APP 
half-life, primarily affecting the APP695 isoform. When NO 
production was inhibited, the basal levels of APP mRNA and 
protein were reduced and the increase in APP protein expres-
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sion normally observed following NGF treatment was pre-
vented. However, in both control and NGF-treated cells, the 
protein half-life of APP was prolonged in the presence of S-
MIU, indicating NO plays a dual role in regulating APP lev-
els. 
  Several APP isoforms can be produced from the APP 
gene however; APP695, APP751, and APP770 predominate 
in most mammalian tissues (reviewed in [19]). These iso-
forms can exist in both immature and mature forms, with 
mature forms being N- and O-glycosylated and tyrosyl sul-
fated as a result of post-translational processing [20]. 
APP695 is highly expressed in neurons [21] and it is the ma-
ture form of this isoform that is phosphorylated during PC12 
cell differentiation [16]. Our finding that NO plays a dual 
role in modulating the levels of the APP695 isoform could 
be important with respect to understanding the regulation of 
neuronal APP expression and the role of both NO and APP 
in neuron function and in regulating the outgrowth of neu-
rites.  
  We and others have reported that NGF enhances the ex-
pression of both APP [7 - 10, 22 - 25] and NOS [11, 12, 26] 
and both NO [11, 12] and APP [16 - 18] have been identified 
as important contributors to neurite extension. While the 
interplay between NO and APP has not been fully eluci-
dated, several studies have highlighted links between APP 
and NO. The c-terminal fragment of APP was reported to 
 
Fig. (4). APP protein levels following cycloheximide treatment in control and NGF-treated PC12 cells grown in the presence or absence of 
S-MIU. Densitometric analysis of mature (m) APP751/770 (A) immature (i) APP751/770 and mAPP695 (B) and iAPP695 (C) protein ex-
pression normalized to -tubulin in untreated (control) and 2.0 mM S-MIU-treated PC12 cells. No difference in relative mAPP751/770 lev-
els was observed between control cells and those grown in the presence of S-MIU but the level of this isoform was significantly higher in 
cells grown in the presence of S-MIU following treatment with cycloheximide for 60 and 120 min (*p<0.05). Relative densities of the bands 
containing APP695 in S-MIU treated PC12 cells were significantly different from control in the absence of cycloheximide (**p<0.01) and 
following 60 and 120 mins of treatment with cycloheximide (*p<0.05; ** p < 0.01). Densitometric analysis of mAPP751/770 (D) 
iAPP751/770 and mAPP695 (E) and iAPP695 (F) protein expression normalized to -tubulin samples obtained from 50 ng/mL NGF-treated 
PC12 cells grown in the presence or absence of 2.0 mM S-MIU. The relative density of bands containing the APP695 isoform was signifi-
cantly different in cells treated with NGF alone compared to cells treated with NGF in the presence of S-MIU in the absence of cyclo-
heximide (*p < 0.05; **p < 0.01) and following 120 mins of treatment with cycloheximide (*p<0.05; **p<0.01). Data are presented as the 
mean ± SEM and represent 5 independent experiments. Statistical significance was determined by performing a one-way ANOVA followed 
by Tukey-Kramer’s multiple comparisons test to determine any significant differences between NGF treated samples grown in the presence 
or absences of S-MIU at each time point. 
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increase iNOS expression and NO production [27, 28] and 
both APP and constitutive NOS were found to be elevated in 
a subset of neurons following injury [29]. We reported pre-
viously that treatment with NOS inhibitors attenuated NGF-
stimulated APP promoter activation and the increase in pro-
tein levels [7]. To further characterize the link between NO 
and APP, the actions of NGF and NOS inhibitors on APP 
mRNA levels and APP protein stability were evaluated.  
  Previous studies reported that NGF induction of APP 
mRNA involves activation of the Ras-MAPK signalling 
pathway [22, 25]. We and others have shown that NO modu-
lates the MAPK signalling pathway [30, 31] suggesting NO 
could also play a role in the regulation of APP mRNA ex-
pression. In contrast to previous reports, using both real-time 
PCR and northern blot analysis, we found that treatment of 
PC12 cells with NGF decreased steady-state APP mRNA 
levels. It is possible that different cell types or lines of PC12 
cells exhibit different gene expression profiles. The PC12 
cells used in the present study were from American Type 
Culture Collection (ATCC, Rockville, MD, USA) while 
other studies investigating APP mRNA levels used primary 
neurons [9] or PC12 cells supplied by Dr. L. Greene [10]. 
The decrease in APP mRNA levels observed in the present 
study  was not isoform specific as the steady-state mRNA 
levels of both APP695 and APP751/770 were below control 
values following treatment with NGF. The observed de-
crease in APP mRNA levels  was surprising as it did not 
correlate our previous NGF-induced transcription and pro-
tein expression findings [7].  Using the same cell line and 
treatment conditions, we reported previously that APP pro-
moter activity was increased following treatment with NGF 
and that the NGF-induced increase in APP protein levels was 
attenuated by pre-treatment with the transcription inhibitor 
actinomycin D [7].Our initial findings agreed with previous 
reports [8-10] and indicated that the NGF-mediated increase 
in APP protein levels was due to increased APP transcription 
however, the data in the present study suggest that this en-
hanced transcription does not result in increased APP mRNA 
levels. Taken together, these findings suggest the enhanced 
transcription of APP induced by NGF is followed by rapid 
translation and degradation of APP mRNA. This rapid deg-
radation of APP mRNA is supported by the lower estimated 
half-life observed in NGF-treated PC12 cells relative to con-
trol, however this difference was not statistically significant 
at the NGF treatment timepoint examined. Interestingly the 
iNOS selective inhibitor S-MIU also reduced APP mRNA 
expression and like NGF, the effect of S-MIU on APP 
mRNA levels was not isoform specific. We reported previ-
ously that S-MIU did not affect basal APP promoter activity 
[7] suggesting that this reduction in APP mRNA levels is 
also due to an alteration in mRNA stability and not the result 
of inhibiting APP transcription. Furthermore, while the lev-
els of both APP695 and APP751/770 mRNA were reduced 
significantly in samples obtained from cells receiving both 
NGF and S-MIU relative to untreated (control) cells, these 
levels were not different from those measured in extracts 
obtained from cells receiving either of these treatments 
alone. This indicates that the effects of NGF and NOS inhi-
bition on steady-state APP mRNA levels are not additive and 
could involve similar mechanisms. The finding in this study 
that APP mRNA expression is decreased in PC12 cells 
treated with NGF or NOS inhibitors is unique and requires 
further investigation. 
  To better understand how NGF and NO were affecting 
APP protein turnover, the effect of cycloheximide on un-
treated PC12 cells and cells treated with NGF or S-MIU 
alone and in combination was evaluated. We reported previ-
ously that the level of the APP695 isoform was increased 
significantly following 96 h of treatment with NGF. To de-
termine whether this increase is due in part to alterations in 
protein stability, cycloheximide was added to PC12 cells 72 
h after NGF treatment was initiated, the time at which the 
trend towards increased APP levels was first observed [7]. In 
the present study no change in the half-life of any of the APP 
isoforms was observed following exposure to NGF. Since 
NGF did not increase the levels of APP mRNA or protein 
stability, our findings suggest that in PC12 cells NGF in-
creases APP protein expression through enhanced transcrip-
tion, followed by rapid translation and degradation of APP 
mRNA. In contrast to NGF, the iNOS-selective inhibitor S-
MIU decreased the relative levels of APP protein in both the 
presence and absence of NGF but the degradation of APP 
was inhibited. These findings suggest that in addition to its 
role in regulating APP transcription NO could modulate 
mRNA stability as well as APP processing. NO was reported 
to increase the activity of tumor necrosis factor -converting 
enzyme (TACE) [32] and under conditions of ischemia, acti-
vation of NOS was found to increase beta-site APP cleavage 
enzyme 1 (BACE-1) expression [33]. If in our system NO 
causes a similar increase the activity or expression of TACE, 
BACE-1 or one of the other -secretase candidates, this 
could affect the level of full-length APP protein detected. 
Similarly, inhibition of NOS could prevent the degradation 
of APP by secretases, resulting in the prolonged half-life of 
this protein. In the present study, treatment of PC12 cells 
with S-MIU resulted in a reduction in the relative levels of 
APP protein and enhanced the protein stability and these 
effects were most consistently observed for the APP695 is-
form. We therefore speculate that NO does indeed modulate 
both the expression and cleavage of neuronal APP. Future 
studies are necessary in order to explore this relatively un-
characterized role of NO.  
  Since APP plays an important role in neuron function and 
its cleavage products are involved in the pathogenesis of AD, 
a better understanding of the mechanisms involved in regu-
lating APP expression and its post-translational processing 
are necessary. The present study demonstrates that the NGF-
mediated increase in APP protein levels is not due to en-
hanced mRNA or protein stability and that NO, which is 
necessary for NGF-induced neurite outgrowth and increased 
APP protein levels in PC12 cells, modulates APP mRNA 
levels and protein stability. NO plays an important role in the 
regulation of APP expression and the neurotrophic actions of 
NGF. Additional studies on the mechanisms involved in 
these complex processes would provide valuable insight into 
the neuromodulatory actions of both NO and APP.  
ABBREVIATIONS 
AD =  Alzheimer’s  disease 
A =  Amyloid  -protein 38    The Open Biochemistry Journal, 2012, Volume 6  MacKinnon et al. 
ANOVA = Analysis  of  variance 
APP =  Amyloid  precursor  protein 
BACE-1  =  Beta-site APP cleavage enzyme 1 
DMEM =  Dulbecco’s  modified Eagle medium 
ECL =  Enhanced  chemiluminescence 
L-NAME =  N
-nitro-L-arginine methyl ester 
NGF  =  Nerve growth factor 
NO =  Nitric  oxide 
NOS  =  Nitric oxide synthase 
PBS =  Phosphate  buffered  saline 
RIPA =  Radioimmunoprecipitation  assay 
SDS  =  Sodium dodecyl sulfate 
SEM  =  Standard error of the mean 
S-MIU =  S-methylisothiourea 
TACE  =  Tumor necrosis factor -converting en-
zyme 
TBS  =  TRIS buffered saline 
TBS-T  =  TBS containing 0.1 % tween 20. 
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